Table 4.

Baseline HPV PCR and HRA results of patients enrolled

Variable	HIV-MSM vaccine (n = 66)	HIV-MSM placebo (n = 63)	p*
PCR of HPV
LR-HPV, n (%)	39 (59)	34 (53.9)	0.63
HR-HPV, n (%)	46 (69.7)	44 (69.8)	0.87
HR and LR HPV, n (%)	28 (42.4)	31 (49.2)	0.39
Number of HR-HPV (IQR)	1 (0–2)	2 (0–3)	0.22
Number of LR-HPV (IQR)	1 (0–2)	1 (0–2)	0.94
Genotypes, n (%)
HPV6	11 (16.6)	8 (12.6)	0.55
HPV11	8 (12.1)	7 (11.1)	0.88
HPV16	15 (22.7)	15 (23.8)	0.85
HPV16 species	22 (33.3)	24 (38.1)	0.49
HPV18	4 (6.1)	5 (7.9)	0.74
HPV18 species	18 (27.3)	22 (34.9)	0.35
Cytology, n (%)
Normal	26 (39.4)	27 (42.9)	0.69
LSIL	34 (51.5)	26 (41.3)	0.24
HSIL	1 (1.5)	4 (6.3)	0.21
ASC	5 (7.6)	6 (9.5)	0.69
HRA, n (%)
Normal	33 (0.5)	29 (46)	0.65
LSIL	33 (0.5)	34 (53.9)	0.65

HRA high resolution anoscopy

* p < 0.05